Hadas Zachor1, Rhoderick Machekano, Michelle M Estrella, Peter J Veldkamp, Michele D Zeier, Olalekan A Uthman, Jantjie J Taljaard, Mohammed R Moosa, Jean B Nachega. 1. aDepartment of Medicine, Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA bBiostatistics Unit, Stellenbosch University, Cape Town, South Africa cDepartment of Medicine, Division of Nephrology, School of Medicine, Johns Hopkins University, Baltimore, Maryland, USA dDepartment of Medicine and Centre for Infectious Diseases, Faculty of Medicine and Health Sciences eCentre for Evidence-Based Healthcare; Stellenbosch University, Cape Town, South Africa fDivision of Health Sciences, Warwick-Centre for Applied Health Research and Delivery (WCAHRD), Warwick Medical School, University of Warwick, Coventry, UK gDepartment of Medicine, Division of Nephrology, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa hDepartments of Epidemiology, Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania iDepartments of Epidemiology and International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, USA.
Abstract
OBJECTIVE: To describe the incidence of rapid kidney function decline (RKFD), and stage 3 chronic kidney disease (CKD) in HIV-1-infected adults initiated on tenofovir-containing antiretroviral therapy. METHODS: A retrospective cohort study at the infectious diseases clinic of Tygerberg Academic Hospital in Cape Town, South Africa. Patients with more than 3 ml/min per year decline in estimated glomerular filtration were classified as having RKFD, and stage 3 CKD was defined as a value less than 60 ml/min per 1.73 m. We used logistic and Cox proportional hazards regression models to determine factors associated with RKFD and stage 3 CKD. RESULTS: Of 650 patients, 361 (55%) experienced RKFD and 15 (2%) developed stage 3 CKD during a median interquartile range follow-up time of 54 (46.6-98) weeks. For every 10-year increase in age and 10 ml/min lower baseline estimated glomerular filtration, the odds of RKFD increased by 70% [adjusted odds ratio = 1.70, 95% confidence interval (CI) 1.36-2.13] and 57% (adjusted odds ratio = 1.57, 95% CI 1.38-1.80), respectively. Each 10-year older age was associated with a 1.90-fold increased risk of developing stage 3 CKD (adjusted hazard ratio = 1.90, 95% CI: 1.10-3.29). Women had about four-fold greater risk of stage 3 CKD compared with men (adjusted hazard ratio = 3.96, 95% CI: 1.06-14.74). CONCLUSION: About half of our study population developed RKFD but only 2% progressed to stage 3 CKD. Approaches that provide balanced allocation of limited resources toward screening and monitoring for kidney dysfunction and HIV disease management are critically needed in this setting.
OBJECTIVE: To describe the incidence of rapid kidney function decline (RKFD), and stage 3 chronic kidney disease (CKD) in HIV-1-infected adults initiated on tenofovir-containing antiretroviral therapy. METHODS: A retrospective cohort study at the infectious diseases clinic of Tygerberg Academic Hospital in Cape Town, South Africa. Patients with more than 3 ml/min per year decline in estimated glomerular filtration were classified as having RKFD, and stage 3 CKD was defined as a value less than 60 ml/min per 1.73 m. We used logistic and Cox proportional hazards regression models to determine factors associated with RKFD and stage 3 CKD. RESULTS: Of 650 patients, 361 (55%) experienced RKFD and 15 (2%) developed stage 3 CKD during a median interquartile range follow-up time of 54 (46.6-98) weeks. For every 10-year increase in age and 10 ml/min lower baseline estimated glomerular filtration, the odds of RKFD increased by 70% [adjusted odds ratio = 1.70, 95% confidence interval (CI) 1.36-2.13] and 57% (adjusted odds ratio = 1.57, 95% CI 1.38-1.80), respectively. Each 10-year older age was associated with a 1.90-fold increased risk of developing stage 3 CKD (adjusted hazard ratio = 1.90, 95% CI: 1.10-3.29). Women had about four-fold greater risk of stage 3 CKD compared with men (adjusted hazard ratio = 3.96, 95% CI: 1.06-14.74). CONCLUSION: About half of our study population developed RKFD but only 2% progressed to stage 3 CKD. Approaches that provide balanced allocation of limited resources toward screening and monitoring for kidney dysfunction and HIV disease management are critically needed in this setting.
Authors: Leonard Msango; Jennifer A Downs; Samuel E Kalluvya; Benson R Kidenya; Rodrick Kabangila; Warren D Johnson; Daniel W Fitzgerald; Robert N Peck Journal: AIDS Date: 2011-07-17 Impact factor: 4.177
Authors: Robert C Kalayjian; Bryan Lau; Rhoderick N Mechekano; Heidi M Crane; Benigno Rodriguez; Robert A Salata; Zipporah Krishnasami; James H Willig; Jeffrey N Martin; Richard D Moore; Joseph J Eron; Mari M Kitahata Journal: AIDS Date: 2012-09-24 Impact factor: 4.177
Authors: Giordano Madeddu; Paolo Bonfanti; Giuseppe V De Socio; Silvia Carradori; Carmela Grosso; Patrizia Marconi; Giovanni Penco; Elena Rosella; Sebastiano Miccolis; Sara Melzi; Maria Stella Mura; Simona Landonio; Elena Ricci; Tiziana Quirino Journal: Biomed Pharmacother Date: 2007-05-29 Impact factor: 6.529
Authors: Benjamin Young; Kate Buchacz; Rose K Baker; Anne C Moorman; Kathy C Wood; Joan Chmiel; John T Brooks Journal: J Int Assoc Physicians AIDS Care (Chic) Date: 2007-06-19
Authors: Michael Horberg; Beth Tang; William Towner; Michael Silverberg; Susan Bersoff-Matcha; Leo Hurley; Joseph Chang; Jackie Blank; Charles Quesenberry; Daniel Klein Journal: J Acquir Immune Defic Syndr Date: 2010-01 Impact factor: 3.731
Authors: Wolfgang Stöhr; A Sarah Walker; Paula Munderi; Stefano Tugume; Charles F Gilks; Janet H Darbyshire; James Hakim Journal: Antivir Ther Date: 2008
Authors: Monica Gandhi; David V Glidden; Kenneth Mayer; Mauro Schechter; Susan Buchbinder; Beatriz Grinsztejn; Sybil Hosek; Martin Casapia; Juan Guanira; Linda-Gail Bekker; Alexander Louie; Howard Horng; Leslie Z Benet; Albert Liu; Robert M Grant Journal: Lancet HIV Date: 2016-08-31 Impact factor: 12.767
Authors: Udeme E Ekrikpo; Andre P Kengne; Aminu K Bello; Emmanuel E Effa; Jean Jacques Noubiap; Babatunde L Salako; Brian L Rayner; Giuseppe Remuzzi; Ikechi G Okpechi Journal: PLoS One Date: 2018-04-16 Impact factor: 3.240
Authors: Nongodo Firmin Kaboré; Armel Poda; Jacques Zoungrana; Ollo Da; Laura Ciaffi; Aoua Semdé; Issouf Yaméogo; Adrien B Sawadogo; Eric Delaporte; Nicolas Meda; Sophie Limou; Amandine Cournil Journal: BMC Nephrol Date: 2019-05-07 Impact factor: 2.388
Authors: Kristin Baltrusaitis; Bonus Makanani; Camlin Tierney; Mary Glenn Fowler; Dhayendre Moodley; Gerhard Theron; Lynette H Nyakudya; Musunga Tomu; Lee Fairlie; Kathleen George; Barbara Heckman; Kevin Knowles; Renee Browning; George K Siberry; Taha E Taha; Lynda Stranix-Chibanda Journal: BMC Infect Dis Date: 2022-07-20 Impact factor: 3.667
Authors: Alexander Gilbert; Lindsey Robertson; Jack E Heron; Steve Chadban; Chiratidzo Ndhlovu; Rumbi F Dahwa; David M Gracey Journal: PLoS One Date: 2020-10-26 Impact factor: 3.240